YD Bio Ltd
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
About YD Bio
Services-Medical Laboratories, SIC 8071
YD Bio Limited is a biotechnology company that develops diagnostic tests and pharmaceutical products. The company focuses on cancer detection and ophthalmic treatments. Its diagnostic portfolio includes blood tests utilizing DNA methylation analysis for pancreatic cancer and breast cancer. In addition, the company develops therapies targeting eye conditions, including dry eye disease, glaucoma, and corneal repair, alongside research into exosome technologies. Its products and diagnostic tests are designed for physicians, patients, healthcare providers, and third-party payors within the medical community.
The company is incorporated in the Cayman Islands and maintains its principal executive offices in Taipei City, Taiwan, where its primary operating subsidiary is located. YD Bio targets markets in the United States and international jurisdictions. The organization relies on collaborative partnerships, licensing agreements, and external contract manufacturers to produce its supplies, without maintaining internal large-scale production facilities.
Summary of the business section of YD Bio's latest annual report, written by StockData.
Company profile
Company
- Legal name
- YD Bio Ltd
- Headquarters
- Taipei City, Taiwan
- Address
- 12f., No. 3, Xingnan St., Nangang Dist. 115001
- Phone
- (619) 500-7747
- Employees
- 13, Dec 31, 2025
- Industry
- Services-Medical Laboratories
- Incorporated in
- E9
- Fiscal year ends
- December 31
- Auditor
- MaloneBailey, LLP, Houston, Texas
Stock & identifiers
- Ticker
- YDES
- Other tickers
- YDESW
- Exchange
- Nasdaq
- IPO date
- Aug 26, 2025
- Shares outstanding
- 71M, Dec 31, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- Stock splits
- 64730-for-1, Apr 30, 2026
- SEC CIK
- 2011674
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Ethan Shen PhD | CEO, Director | 54,379,189 |
| Bo-Xiang Zhang | Chief Medical Officer, Director | 31,141 |
| Man Edmund Hen | Chief Financial Officer | – |
| Kochi Chang | Director | 7,830 |
| Shao-Ta Lu | Director | 58,981 |
| Jerry Yin-Chia Lee | Director | – |
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Aug 20, 2025 | Listing | Registration of securities on an exchange (Form 8-A) |
| Nov 25, 2024 | Merger | Registration of securities for a merger or exchange offer (S-4) |
| Jun 21, 2024 | Name change | Name changed from True Velocity, Inc./DE to YD Bio Ltd |
| Feb 14, 2024 | Merger | Registration of securities for a merger or exchange offer (S-4) |